KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.6026
-0.0724 (-10.73%)
At close: Jan 20, 2026, 4:00 PM EST
0.6170
+0.0144 (2.39%)
Pre-market: Jan 21, 2026, 5:15 AM EST
Company Description
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases.
The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases.
Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | David Lazar |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Elliot Lazar | Chief Executive Officer, Chief Financial Officer, President, Chief Operating Officer and Chair of the Board |
| Dr. R. Kim Brazzell Ph.D. | Head of Research & Development and Chief Medical Officer |
| Todd Bazemore | Principal Executive Officer and Director |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Mary Reumuth CPA | Treasurer and Secretary |
| Josiah Craver | Senior Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 424B5 | Filing |
| Jan 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 6, 2026 | 8-K | Current Report |
| Jan 2, 2026 | 8-K | Current Report |
| Dec 30, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 29, 2025 | 8-K | Current Report |
| Dec 19, 2025 | PRER14A | Filing |
| Dec 16, 2025 | 8-K | Current Report |